The development of new cancer therapies based on the molecular identification of cancer regression antigens.

S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

Knowledge of the nature of immune reactivity to human tumors has increased dramatically in the past decade. Prior to this, there was significant doubt as to whether tumor antigens actually existed on growing human cancers, and if so, there was considerable skepticism about whether immunotherapies could ever be used to affect growing tumors. The development of reproducible techniques for generating human lymphocytes with reactivity against tumor antigens, the demonstration that the recognition of tumor antigens obeys the same immunologic laws of MHC restriction that characterize immunologic reactions against other antigens, and the demonstration that T-cell transfer therapies--as well as immunotherapies using immune stimulants such as IL-2--could cause the regression of established growing cancers in humans have transformed the study of human tumor immunology from a speculative science to one with concrete applications to the treatment of patients with cancer. The cloning of the genes encoding cancer antigens and the molecular identification of the encoded proteins has opened new possibilities for the development of cancer treatments. Although several human cancer antigens have been identified, only a small number of histologic types of tumors have been studied and these investigations need to be extended to identify putative tumor antigens expressed on common epithelial neoplasms. There is considerable uncertainty surrounding the mechanism by which immune reactions to these cancer antigens are generated in humans. Thus far, all of the cancer rejection antigens recognized by TIL, as well as additional antigens described by others, represent antigens that are encoded by normal nonmutated genes that are expressed on selected normal tissues as well as on tumors. An understanding of the mechanisms by which the tumor can break tolerance to these normal antigens represents a significant challenge to immunologic studies, the answer to which may provide additional insight into methods for enhancing antitumor immune responses.

Original languageEnglish (US)
Pages (from-to)90-100
Number of pages11
JournalCancer Journal from Scientific American
Volume1
Issue number2
StatePublished - Jul 1995
Externally publishedYes

Fingerprint

Antigens
Neoplasms
Neoplasm Antigens
Therapeutics
Immunotherapy
Glandular and Epithelial Neoplasms
Neoplasm Genes
Cell- and Tissue-Based Therapy
Allergy and Immunology
Uncertainty
Interleukin-2
Organism Cloning
Lymphocytes
T-Lymphocytes
Genes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The development of new cancer therapies based on the molecular identification of cancer regression antigens. / Rosenberg, S. A.

In: Cancer Journal from Scientific American, Vol. 1, No. 2, 07.1995, p. 90-100.

Research output: Contribution to journalArticle

@article{de23f942f2cd4af8abbbd9d1e990c115,
title = "The development of new cancer therapies based on the molecular identification of cancer regression antigens.",
abstract = "Knowledge of the nature of immune reactivity to human tumors has increased dramatically in the past decade. Prior to this, there was significant doubt as to whether tumor antigens actually existed on growing human cancers, and if so, there was considerable skepticism about whether immunotherapies could ever be used to affect growing tumors. The development of reproducible techniques for generating human lymphocytes with reactivity against tumor antigens, the demonstration that the recognition of tumor antigens obeys the same immunologic laws of MHC restriction that characterize immunologic reactions against other antigens, and the demonstration that T-cell transfer therapies--as well as immunotherapies using immune stimulants such as IL-2--could cause the regression of established growing cancers in humans have transformed the study of human tumor immunology from a speculative science to one with concrete applications to the treatment of patients with cancer. The cloning of the genes encoding cancer antigens and the molecular identification of the encoded proteins has opened new possibilities for the development of cancer treatments. Although several human cancer antigens have been identified, only a small number of histologic types of tumors have been studied and these investigations need to be extended to identify putative tumor antigens expressed on common epithelial neoplasms. There is considerable uncertainty surrounding the mechanism by which immune reactions to these cancer antigens are generated in humans. Thus far, all of the cancer rejection antigens recognized by TIL, as well as additional antigens described by others, represent antigens that are encoded by normal nonmutated genes that are expressed on selected normal tissues as well as on tumors. An understanding of the mechanisms by which the tumor can break tolerance to these normal antigens represents a significant challenge to immunologic studies, the answer to which may provide additional insight into methods for enhancing antitumor immune responses.",
author = "Rosenberg, {S. A.}",
year = "1995",
month = "7",
language = "English (US)",
volume = "1",
pages = "90--100",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

TY - JOUR

T1 - The development of new cancer therapies based on the molecular identification of cancer regression antigens.

AU - Rosenberg, S. A.

PY - 1995/7

Y1 - 1995/7

N2 - Knowledge of the nature of immune reactivity to human tumors has increased dramatically in the past decade. Prior to this, there was significant doubt as to whether tumor antigens actually existed on growing human cancers, and if so, there was considerable skepticism about whether immunotherapies could ever be used to affect growing tumors. The development of reproducible techniques for generating human lymphocytes with reactivity against tumor antigens, the demonstration that the recognition of tumor antigens obeys the same immunologic laws of MHC restriction that characterize immunologic reactions against other antigens, and the demonstration that T-cell transfer therapies--as well as immunotherapies using immune stimulants such as IL-2--could cause the regression of established growing cancers in humans have transformed the study of human tumor immunology from a speculative science to one with concrete applications to the treatment of patients with cancer. The cloning of the genes encoding cancer antigens and the molecular identification of the encoded proteins has opened new possibilities for the development of cancer treatments. Although several human cancer antigens have been identified, only a small number of histologic types of tumors have been studied and these investigations need to be extended to identify putative tumor antigens expressed on common epithelial neoplasms. There is considerable uncertainty surrounding the mechanism by which immune reactions to these cancer antigens are generated in humans. Thus far, all of the cancer rejection antigens recognized by TIL, as well as additional antigens described by others, represent antigens that are encoded by normal nonmutated genes that are expressed on selected normal tissues as well as on tumors. An understanding of the mechanisms by which the tumor can break tolerance to these normal antigens represents a significant challenge to immunologic studies, the answer to which may provide additional insight into methods for enhancing antitumor immune responses.

AB - Knowledge of the nature of immune reactivity to human tumors has increased dramatically in the past decade. Prior to this, there was significant doubt as to whether tumor antigens actually existed on growing human cancers, and if so, there was considerable skepticism about whether immunotherapies could ever be used to affect growing tumors. The development of reproducible techniques for generating human lymphocytes with reactivity against tumor antigens, the demonstration that the recognition of tumor antigens obeys the same immunologic laws of MHC restriction that characterize immunologic reactions against other antigens, and the demonstration that T-cell transfer therapies--as well as immunotherapies using immune stimulants such as IL-2--could cause the regression of established growing cancers in humans have transformed the study of human tumor immunology from a speculative science to one with concrete applications to the treatment of patients with cancer. The cloning of the genes encoding cancer antigens and the molecular identification of the encoded proteins has opened new possibilities for the development of cancer treatments. Although several human cancer antigens have been identified, only a small number of histologic types of tumors have been studied and these investigations need to be extended to identify putative tumor antigens expressed on common epithelial neoplasms. There is considerable uncertainty surrounding the mechanism by which immune reactions to these cancer antigens are generated in humans. Thus far, all of the cancer rejection antigens recognized by TIL, as well as additional antigens described by others, represent antigens that are encoded by normal nonmutated genes that are expressed on selected normal tissues as well as on tumors. An understanding of the mechanisms by which the tumor can break tolerance to these normal antigens represents a significant challenge to immunologic studies, the answer to which may provide additional insight into methods for enhancing antitumor immune responses.

UR - http://www.scopus.com/inward/record.url?scp=33750113849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750113849&partnerID=8YFLogxK

M3 - Article

C2 - 9166458

AN - SCOPUS:33750113849

VL - 1

SP - 90

EP - 100

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 2

ER -